Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.34
BCRX's Cash to Debt is ranked lower than
68% of the 895 Companies
in the Global Biotechnology industry.

( Industry Median: 27.79 vs. BCRX: 2.34 )
Ranked among companies with meaningful Cash to Debt only.
BCRX' s Cash to Debt Range Over the Past 10 Years
Min: 0.94  Med: 10000.00 Max: 11087.67
Current: 2.34
0.94
11087.67
Equity to Asset 0.46
BCRX's Equity to Asset is ranked lower than
72% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. BCRX: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
BCRX' s Equity to Asset Range Over the Past 10 Years
Min: -0.23  Med: 0.65 Max: 0.98
Current: 0.46
-0.23
0.98
F-Score: 4
Z-Score: -1.09
M-Score: 9.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -76.18
BCRX's Operating margin (%) is ranked lower than
51% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -70.14 vs. BCRX: -76.18 )
Ranked among companies with meaningful Operating margin (%) only.
BCRX' s Operating margin (%) Range Over the Past 10 Years
Min: -17879.61  Med: -153.07 Max: -18.42
Current: -76.18
-17879.61
-18.42
Net-margin (%) -74.45
BCRX's Net-margin (%) is ranked lower than
52% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -66.97 vs. BCRX: -74.45 )
Ranked among companies with meaningful Net-margin (%) only.
BCRX' s Net-margin (%) Range Over the Past 10 Years
Min: -17170.39  Med: -161.18 Max: -18.03
Current: -74.45
-17170.39
-18.03
ROE (%) -50.27
BCRX's ROE (%) is ranked lower than
64% of the 807 Companies
in the Global Biotechnology industry.

( Industry Median: -31.22 vs. BCRX: -50.27 )
Ranked among companies with meaningful ROE (%) only.
BCRX' s ROE (%) Range Over the Past 10 Years
Min: -544.61  Med: -67.52 Max: -20.28
Current: -50.27
-544.61
-20.28
ROA (%) -26.38
BCRX's ROA (%) is ranked higher than
50% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. BCRX: -26.38 )
Ranked among companies with meaningful ROA (%) only.
BCRX' s ROA (%) Range Over the Past 10 Years
Min: -59.43  Med: -44.15 Max: -11.86
Current: -26.38
-59.43
-11.86
ROC (Joel Greenblatt) (%) -4701.83
BCRX's ROC (Joel Greenblatt) (%) is ranked lower than
79% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -378.42 vs. BCRX: -4701.83 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BCRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -15669.01  Med: -399.25 Max: -202.66
Current: -4701.83
-15669.01
-202.66
Revenue Growth (3Y)(%) -23.10
BCRX's Revenue Growth (3Y)(%) is ranked lower than
74% of the 440 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. BCRX: -23.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BCRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.5  Med: -14.05 Max: 430.1
Current: -23.1
-68.5
430.1
EBITDA Growth (3Y)(%) -19.70
BCRX's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 454 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. BCRX: -19.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BCRX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -41.9  Med: -5.15 Max: 64.5
Current: -19.7
-41.9
64.5
EPS Growth (3Y)(%) -18.70
BCRX's EPS Growth (3Y)(%) is ranked lower than
68% of the 462 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. BCRX: -18.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BCRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -38.6  Med: -4.40 Max: 52
Current: -18.7
-38.6
52
» BCRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

BCRX Guru Trades in Q2 2014

George Soros Sold Out
Jim Simons Sold Out
» More
Q1 2015

BCRX Guru Trades in Q1 2015

Jim Simons 32,403 sh (New)
» More
Q2 2015

BCRX Guru Trades in Q2 2015

Paul Tudor Jones 13,308 sh (New)
Steven Cohen 2,000 sh (New)
Jim Simons Sold Out
» More
Q3 2015

BCRX Guru Trades in Q3 2015

Paul Tudor Jones 29,535 sh (+121.93%)
Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 7.06
BCRX's P/B is ranked lower than
92% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. BCRX: 7.06 )
Ranked among companies with meaningful P/B only.
BCRX' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 7.31 Max: 122.5
Current: 7.06
1.04
122.5
P/S 9.07
BCRX's P/S is ranked higher than
50% of the 1125 Companies
in the Global Biotechnology industry.

( Industry Median: 9.13 vs. BCRX: 9.07 )
Ranked among companies with meaningful P/S only.
BCRX' s P/S Range Over the Past 10 Years
Min: 0.73  Med: 7.55 Max: 2000
Current: 9.07
0.73
2000
Current Ratio 1.31
BCRX's Current Ratio is ranked lower than
85% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. BCRX: 1.31 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 6.52 Max: 39.53
Current: 1.31
1.31
39.53
Quick Ratio 1.31
BCRX's Quick Ratio is ranked lower than
81% of the 887 Companies
in the Global Biotechnology industry.

( Industry Median: 4.43 vs. BCRX: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 6.52 Max: 39.53
Current: 1.31
1.3
39.53
Days Inventory 101.84
BCRX's Days Inventory is ranked higher than
58% of the 414 Companies
in the Global Biotechnology industry.

( Industry Median: 124.17 vs. BCRX: 101.84 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 252.26  Med: 692.66 Max: 15234.51
Current: 101.84
252.26
15234.51
Days Sales Outstanding 55.72
BCRX's Days Sales Outstanding is ranked higher than
58% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: 62.58 vs. BCRX: 55.72 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.54  Med: 170.94 Max: 72039.47
Current: 55.72
44.54
72039.47
Days Payable 721.98
BCRX's Days Payable is ranked higher than
98% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 57.61 vs. BCRX: 721.98 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 1451.49  Med: 10988.71 Max: 34806.57
Current: 721.98
1451.49
34806.57

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 47.23
BCRX's Price/Net Current Asset Value is ranked lower than
93% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: 7.24 vs. BCRX: 47.23 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BCRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.59  Med: 6.28 Max: 87.69
Current: 47.23
0.59
87.69
Price/Tangible Book 7.06
BCRX's Price/Tangible Book is ranked lower than
67% of the 1054 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. BCRX: 7.06 )
Ranked among companies with meaningful Price/Tangible Book only.
BCRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.33  Med: 4.34 Max: 121.33
Current: 7.06
0.33
121.33
Price/Median PS Value 1.23
BCRX's Price/Median PS Value is ranked lower than
67% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. BCRX: 1.23 )
Ranked among companies with meaningful Price/Median PS Value only.
BCRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.12  Med: 2.90 Max: 122.25
Current: 1.23
0.12
122.25
Earnings Yield (Greenblatt) (%) -7.73
BCRX's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. BCRX: -7.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BCRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -7.73  Med: 495.80 Max: 1563.9
Current: -7.73
-7.73
1563.9

More Statistics

Revenue(Mil) $49
EPS $ -0.51
Beta2.68
Short Percentage of Float19.21%
52-Week Range $6.09 - 16.83
Shares Outstanding(Mil)73.34

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 50 35 82 53
EPS($) -0.66 -0.81 -0.28 -0.73
EPS without NRI($) -0.66 -0.81 -0.28 -0.73

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc. is a Delaware corporation originally founded in 1986. The Company is engaged in the design, optimization and development of novel drugs that block key enzymes involved in the pathogenesis of diseases. It integrates the disciplines of biology, crystallography, medicinal chemistry and computer modeling to discover and develop small molecule pharmaceuticals through the process known as structure-guided drug design. It uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include Peramivir, BCX4161, Two 2nd generation HAE compounds, BCX4430, Forodesine and Ulodesine. Peramivir is a neuraminidase inhibitor for the treatment of patients with influenza and a potent, intravenously administered antiviral agent that rapidly delivers high plasma concentrations to the sites of infection. BCX4161 is a novel, selective inhibitor of plasma kallikrein in development as an orally-administered treatment for the prevention of attacks in patients with Hereditary Angioedema. Forodesine is a PNP inhibitor in development as a treatment for cancer. Ulodesine is a PNP inhibitor developed as a once-daily oral, chronic treatment for gout. The Company's product candidates are subject to extensive and rigorous domestic government regulations prior to commercialization.
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,249 Shares Apr 06 2010 

More From Other Websites
WHO Declares Zika A Health Emergency of International Concern: 5 Companies Developing Technologies... Feb 03 2016
Billionaire Ubben Cuts Stake in Adobe (ADBE), Carlson Buys More Archrock (AROC), and 2 Other Moves Jan 28 2016
5 Stocks Insiders Love Right Now Jan 27 2016
Warren Buffett Continues Massive Energy Insider Buying: Phillips 66, Summit Midstream, Lands’ End... Jan 23 2016
These 4 Stocks Were Just Bought by Baker Bros. Advisors, Clint Carlson, More Jan 22 2016
Jefferies Has 5 Top Growth Stocks to Buy After Horrible 2016 Start Jan 12 2016
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Jan 08 2016
Jefferies' Best Biotech Ideas For 2016 (And Beyond) Jan 06 2016
BioCryst Pharma upgraded by Jefferies Jan 06 2016
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : January 5,... Jan 05 2016
BioCryst to Present at the J.P. Morgan Healthcare Conference Jan 04 2016
BioCryst to Present at the J.P. Morgan Healthcare Conference Jan 04 2016
BioCryst Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 16 2015
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 14,... Dec 14 2015
BIOCRYST PHARMACEUTICALS INC Financials Dec 08 2015
4 Key FDA Decisions Expected By Year End Nov 28 2015
Should You Buy Theravance Inc (THRX)? Nov 27 2015
BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : November 25, 2015 Nov 25 2015
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : November 25,... Nov 25 2015
Hedge Fund Sentiment Is Stagnant On Ocwen Financial Corporation (OCN) Nov 25 2015
BioCryst To Present At Two Upcoming Investor Conferences Nov 24 2015
BioCryst To Present At Two Upcoming Investor Conferences Nov 24 2015
BioCryst and Intercept Drive Biotechnology Subgroup Nov 12 2015
Elite Hedge Funds Making Moves in These Three Stocks Nov 07 2015
BioCryst reports 3Q loss Nov 05 2015
BioCryst Reports Third Quarter 2015 Financial Results Nov 05 2015
Biocryst to Present at the Jefferies Autumn 2015 Global Healthcare Conference Nov 04 2015
BioCryst to Announce Third Quarter 2015 Financial Results November 5 Oct 27 2015
Sanj K. Patel Appointed to BioCryst's Board of Directors Sep 29 2015
BioCryst Reports Second Quarter 2015 Financial Results Aug 07 2015
Robert Ingram Appointed to BioCryst's Board of Directors Aug 06 2015
BioCryst to Announce Second Quarter 2015 Financial Results August 7 Jul 23 2015
BioCryst to Present at the JMP Securities Life Sciences Conference Jun 18 2015
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited Jun 17 2015
BioCryst to Present at the Jefferies 2015 Healthcare Conference May 26 2015
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary... May 13 2015
BioCryst reports 1Q loss May 08 2015
BioCryst to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference May 05 2015
BioCryst to Announce First Quarter 2015 Financial Results May 8 Apr 23 2015
BioCryst to Present at the Needham Healthcare Conference Apr 07 2015
BioCryst Awarded BCX4430 Advanced Development Contract Mar 31 2015
BioCryst reports 4Q loss Feb 18 2015
BioCryst Reports Fourth Quarter & Full Year 2014 Financial Results Feb 18 2015
BioCryst to Announce 2014 Financial Results February 18 & Present at the 2015 Leerink Global... Feb 05 2015
BioCryst gets FDA approval for flu drug Rapivab Dec 22 2014
BioCryst says FDA approves oral flu drug Rapivab Dec 22 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK